Logo Image
|Articles|May 26, 2023

Xacduro, A New Weapon in the Fight Against Bacterial Pneumonia: Insights From Clinical Trials and Expert Interviews

Author(s)Nina Cosdon

The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.

On Tuesday, the antibiotic Xacduro was approved by the US Food and Drug Administration (FDA) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii-calcoaceticus (ABC) in patients 18 years of age and older.

Xacduro (sulbactam-durlobactam; SUL-DUR) is an intravenous investigational therapy that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor. SUL-DUR targets ABC infections, including those caused by multidrug-resistant and carbapenem-resistant (CRAB) strains.

Contagion has been following this exciting new agent for a while and has compiled 5 of our most recent and relevant pieces of content. Dive into these clinical trials and interviews with experts to learn more about how Xacduro could be a game-changer in the fight against highly resistant pathogens.

Related to this article

View more
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Read more